Royalty Pharma plc - Laporan Laba Rugi (TTM)

Royalty Pharma plc
US ˙ NasdaqGS ˙ GB00BMVP7Y09

Laporan Laba Rugi (TTM)

Laporan Laba Rugi Royalty Pharma plc menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 2,008 2,122 2,195 2,239 2,286 2,289 2,278 2,259 2,247 2,237 2,359 2,361 2,324 2,355 2,239 2,238 2,266 2,264 2,264 2,305
Change (%) 5.71 3.40 2.01 2.12 0.16 -0.48 -0.83 -0.54 -0.44 5.45 0.10 -1.57 1.30 -4.93 -0.04 1.27 -0.11 0.01 1.83
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales -818 231 435 144 316 453 345 695 862 904 838 974 946 561 1,025 997 492 732 22 -395
Change (%) -128.23 88.48 -66.89 119.15 43.45 -23.77 101.24 24.07 4.91 -7.28 16.16 -2.87 -40.74 82.90 -2.81 -50.64 48.90 -97.03 -1,916.89
% of Revenue -40.73 10.88 19.83 6.43 13.81 19.78 15.15 30.75 38.36 40.42 35.54 41.24 40.70 23.81 45.81 44.54 21.71 32.36 0.96 -17.12
Gross Operating Profit 2,825 1,892 1,759 2,094 1,970 1,837 1,933 1,565 1,385 1,333 1,521 1,387 1,378 1,794 1,213 1,241 1,774 1,531 2,242 2,700
Change (%) -33.05 -6.98 19.04 -5.93 -6.78 5.26 -19.06 -11.47 -3.78 14.08 -8.76 -0.66 30.16 -32.38 2.30 42.96 -13.70 46.44 20.42
% of Revenue 140.73 89.12 80.17 93.57 86.19 80.22 84.85 69.25 61.64 59.58 64.46 58.76 59.30 76.19 54.19 55.46 78.29 67.64 99.04 117.12
SG&A 155 182 187 189 187 183 191 198 200 227 261 257 264 250 222 229 228 237 290 479
Change (%) 17.50 2.80 1.14 -1.13 -2.12 4.59 3.62 1.06 13.52 15.03 -1.61 2.54 -5.32 -11.23 3.19 -0.22 3.68 22.42 65.20
% of Revenue 7.70 8.56 8.51 8.44 8.17 7.99 8.39 8.77 8.91 10.16 11.08 10.89 11.35 10.61 9.90 10.22 10.07 10.46 12.80 20.76
R&D 34 26 21 19 104 200 298 295 230 177 77 77 102 52 52 52 2 2 52 352
Change (%) -23.53 -19.01 -12.46 458.23 92.31 48.91 -0.84 -22.00 -23.14 -56.46 -0.14 32.47 -49.02 0.00 0.00 -96.15 0.00 2,500.00 576.92
% of Revenue 1.71 1.24 0.97 0.83 4.55 8.74 13.08 13.08 10.25 7.92 3.27 3.26 4.39 2.21 2.32 2.32 0.09 0.09 2.30 15.27
OpEx -606 462 666 375 630 859 857 1,205 1,304 1,314 1,177 1,308 1,312 862 1,299 1,277 722 971 363 436
Change (%) -176.28 44.23 -43.77 68.04 36.42 -0.16 40.61 8.17 0.79 -10.45 11.15 0.28 -34.26 50.64 -1.67 -43.47 34.47 -62.58 19.96
% of Revenue -30.16 21.76 30.36 16.73 27.54 37.51 37.63 53.35 58.03 58.75 49.89 55.40 56.44 36.63 58.04 57.09 31.87 42.90 16.05 18.91
Operating Income 2,613 1,660 1,528 1,864 1,656 1,431 1,421 1,054 943 923 1,182 1,053 1,012 1,492 939 960 1,544 1,292 1,900 1,869
Change (%) -36.46 -7.96 21.96 -11.13 -13.63 -0.67 -25.84 -10.52 -2.15 28.09 -10.91 -3.87 47.38 -37.04 2.21 60.78 -16.28 47.04 -1.64
% of Revenue 130.16 78.24 69.64 83.27 72.46 62.49 62.37 46.65 41.97 41.25 50.11 44.60 43.56 63.37 41.96 42.91 68.13 57.10 83.95 81.09
Interest Expense -187 -168 -152 -144 -157 -166 -176 -185 -188 -188 -188 -188 -187 -187 -184 -187 -207 -226 -247 -266
Change (%) -10.31 -9.63 -5.05 8.94 5.82 5.81 5.43 1.43 -0.01 -0.06 -0.01 -0.50 0.16 -1.45 1.12 10.98 8.94 9.33 7.97
% of Revenue -9.33 -7.91 -6.92 -6.44 -6.87 -7.26 -7.72 -8.20 -8.37 -8.40 -7.96 -7.95 -8.04 -7.95 -8.24 -8.34 -9.14 -9.96 -10.89 -11.55
Net Income 2,224 975 973 972 783 620 602 466 507 43 332 255 184 1,135 799 673 1,145 859 1,093 1,021
Change (%) -56.17 -0.22 -0.13 -19.42 -20.84 -2.80 -22.62 8.74 -91.55 674.72 -23.17 -27.67 515.39 -29.61 -15.73 70.09 -24.99 27.19 -6.57
% of Revenue 110.79 45.94 44.33 43.40 34.25 27.07 26.44 20.63 22.55 1.91 14.07 10.80 7.93 48.20 35.69 30.09 50.53 37.95 48.26 44.28

Source: Capital IQ

Other Listings
DE:RPD € 30.68
MX:RPRX N
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista